Your browser doesn't support javascript.
loading
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Bollard, Julien; Miguela, Verónica; Ruiz de Galarreta, Marina; Venkatesh, Anu; Bian, C Billie; Roberto, Mark P; Tovar, Victoria; Sia, Daniela; Molina-Sánchez, Pedro; Nguyen, Christie B; Nakagawa, Shigeki; Llovet, Josep M; Hoshida, Yujin; Lujambio, Amaia.
Afiliación
  • Bollard J; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Miguela V; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Ruiz de Galarreta M; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Venkatesh A; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Bian CB; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Roberto MP; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Tovar V; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Sia D; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA.
  • Molina-Sánchez P; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA.
  • Nguyen CB; Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit and Pathology Department, IDIBAPS, Hospital Clínic, CIBERehd, Universitat de Barcelona, Barcelona, Spain.
  • Nakagawa S; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Llovet JM; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Hoshida Y; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Lujambio A; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA.
Gut ; 66(7): 1286-1296, 2017 07.
Article en En | MEDLINE | ID: mdl-27849562
OBJECTIVE: Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that palbociclib could potentially be used for HCC therapy. Here, we provide a comprehensive characterisation of the efficacy of palbociclib in multiple preclinical models of HCC. DESIGN: The effects of palbociclib on cell proliferation, cellular senescence and cell death were investigated in a panel of human liver cancer cell lines, in ex vivo human HCC samples, in a genetically engineered mouse model of liver cancer, and in human HCC xenografts in vivo. The mechanisms of intrinsic and acquired resistance to palbociclib were assessed in human liver cancer cell lines and human HCC samples by protein and gene expression analyses. RESULTS: Palbociclib suppressed cell proliferation in human liver cancer cell lines by promoting a reversible cell cycle arrest. Intrinsic and acquired resistance to palbociclib was determined by loss of RB1. A signature of 'RB1 loss of function' was found in <30% of HCC samples. Palbociclib, alone or combined with sorafenib, the standard of care for HCC, impaired tumour growth in vivo and significantly increased survival. CONCLUSIONS: Palbociclib shows encouraging results in preclinical models of HCC and represents a novel therapeutic strategy for HCC treatment, alone or particularly in combination with sorafenib. Palbociclib could potentially benefit patients with RB1-proficient tumours, which account for 70% of all patients with HCC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Piridinas / Carcinoma Hepatocelular / Inhibidores de Proteínas Quinasas / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Gut Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Piridinas / Carcinoma Hepatocelular / Inhibidores de Proteínas Quinasas / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Gut Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido